SG11201907084VA - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy

Info

Publication number
SG11201907084VA
SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA
Authority
SG
Singapore
Prior art keywords
international
loos
pct
danel
leonard
Prior art date
Application number
SG11201907084VA
Inventor
Emeline Descamps
Robert Walczak
Carole Belanger
Benoît Noel
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201907084VA publication Critical patent/SG11201907084VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

WO 18/ 15408 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT ill mu °mons °nolo OH 100 Ho oinio oimIE (10) International Publication Number WO 2018/154081 Al (51) International Patent Classification: A61K 31/41 78 (2006.01) A61K 31/192 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/EP2018/054588 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305213.5 24 February 2017 (24.02.2017) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: DESCAMPS, Emeline; 9 me Leonard Danel, 59120 LOOS (FR). WALCZAK, Robert; Residence Parc d'Isly, 13B me Delezenne, 59000 LILLE (FR). BE- LANGER, Carole; 3 Allee du Verger, 59910 BONDUES (FR). NOEL, Benoit; 9 me Leonard Danel, 59120 Loos (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY (57) : The present invention relates to a combination of active ingredients for use in the treatment of diseases.
SG11201907084VA 2017-02-24 2018-02-23 Pharmaceutical compositions for combination therapy SG11201907084VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305213 2017-02-24
PCT/EP2018/054588 WO2018154081A1 (en) 2017-02-24 2018-02-23 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
SG11201907084VA true SG11201907084VA (en) 2019-09-27

Family

ID=58231557

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907084VA SG11201907084VA (en) 2017-02-24 2018-02-23 Pharmaceutical compositions for combination therapy

Country Status (14)

Country Link
US (1) US11590108B2 (en)
EP (1) EP3585384A1 (en)
JP (1) JP2020510651A (en)
KR (1) KR102633249B1 (en)
CN (1) CN110418641A (en)
AU (1) AU2018223976B2 (en)
BR (1) BR112019017314A2 (en)
CA (1) CA3051977A1 (en)
EA (1) EA201991990A1 (en)
IL (1) IL268708B (en)
MX (1) MX2019009909A (en)
PH (1) PH12019501820A1 (en)
SG (1) SG11201907084VA (en)
WO (1) WO2018154081A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220133666A1 (en) * 2016-03-31 2022-05-05 Genfit Methods of treatment of cholestatic diseases
CN114796237B (en) * 2016-03-31 2024-02-23 基恩菲特公司 Method for treating cholestatic diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002328092A1 (en) 2001-08-08 2003-02-24 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
FR2841900B1 (en) 2002-07-08 2007-03-02 Genfit S A NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES
CN102647982B (en) 2009-11-26 2014-10-15 基恩菲特公司 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
CN107375932B (en) * 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 Bile acid recirculation inhibitor for treating children cholestatic liver disease
WO2015143367A2 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
EP3191100A4 (en) * 2014-09-12 2018-05-30 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN114796237B (en) 2016-03-31 2024-02-23 基恩菲特公司 Method for treating cholestatic diseases
EP3442518B1 (en) 2016-04-11 2024-01-17 Genfit Methods of treatment for cholestatic and fibrotic diseases
JOP20190040A1 (en) * 2016-09-14 2019-03-10 Novartis Ag Combination of fxr agonists
EP3573614A1 (en) 2017-01-27 2019-12-04 Genfit Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
US11590108B2 (en) 2023-02-28
MX2019009909A (en) 2019-10-14
BR112019017314A2 (en) 2020-04-14
EP3585384A1 (en) 2020-01-01
US20190388394A1 (en) 2019-12-26
KR102633249B1 (en) 2024-02-02
IL268708A (en) 2019-10-31
PH12019501820A1 (en) 2020-09-14
AU2018223976A1 (en) 2019-09-05
EA201991990A1 (en) 2020-04-07
CA3051977A1 (en) 2018-08-30
IL268708B (en) 2022-05-01
AU2018223976B2 (en) 2023-08-17
JP2020510651A (en) 2020-04-09
KR20190119097A (en) 2019-10-21
WO2018154081A1 (en) 2018-08-30
CN110418641A (en) 2019-11-05

Similar Documents

Publication Publication Date Title
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201907034PA (en) Methods of treating influenza
SG11201901390TA (en) Tetracycline compounds and methods of treatment
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11202000494UA (en) Drug delivery composition
SG11201808540SA (en) Methods of treatment for cholestatic and fibrotic diseases